Busey Bank Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Busey Bank cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.7% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,563 shares of the biopharmaceutical company’s stock after selling 227 shares during the period. Busey Bank’s holdings in Regeneron Pharmaceuticals were worth $1,643,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of REGN. SteelPeak Wealth LLC raised its position in shares of Regeneron Pharmaceuticals by 173.0% during the 2nd quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock valued at $1,148,000 after purchasing an additional 692 shares during the period. Atria Investments Inc increased its stake in Regeneron Pharmaceuticals by 12.2% in the 1st quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock worth $8,317,000 after buying an additional 941 shares in the last quarter. Tri Locum Partners LP raised its holdings in Regeneron Pharmaceuticals by 104.5% during the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock valued at $18,410,000 after acquiring an additional 8,949 shares during the period. Nordea Investment Management AB lifted its position in shares of Regeneron Pharmaceuticals by 23.2% in the first quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock valued at $28,218,000 after acquiring an additional 5,495 shares in the last quarter. Finally, Tidal Investments LLC boosted its stake in shares of Regeneron Pharmaceuticals by 16.8% in the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock worth $4,774,000 after acquiring an additional 711 shares during the period. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on REGN shares. Cantor Fitzgerald reissued a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday. Barclays cut their price objective on shares of Regeneron Pharmaceuticals from $1,220.00 to $1,080.00 and set an “overweight” rating for the company in a report on Wednesday. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $1,260.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday. Finally, Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a report on Friday, August 2nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,101.00.

Regeneron Pharmaceuticals Stock Down 1.3 %

Shares of REGN opened at $928.90 on Friday. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 52-week low of $769.19 and a 52-week high of $1,211.20. The company has a market cap of $102.40 billion, a PE ratio of 24.60, a P/E/G ratio of 3.29 and a beta of 0.12. The business has a fifty day moving average of $1,098.29 and a 200 day moving average of $1,040.67.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business’s revenue was up 12.3% on a year-over-year basis. During the same quarter last year, the business earned $8.79 EPS. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.66 EPS for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the transaction, the vice president now owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the transaction, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.